MedTrace Logo

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT06702995 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2025-04-20

No results posted yet for this study

Summary

In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.

Conditions

  • Metastatic Castrate-Resistant Prostate Cancer
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG

XNW5004

Oral continuous

DRUG

enzalutamide

enzalutamide 160 mg (four 40 mg capsules) orally once daily

Sponsors & Collaborators

  • Evopoint Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • D Ye, M.D. · Dingwei Ye

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-19
Primary Completion
2026-05-13
Completion
2026-07-19
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06702995 on ClinicalTrials.gov